Current status and characteristics of <i>BRCA</i> examination at our hospital

DOI
  • Mizoguchi Kimihisa
    Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University
  • Morisaki Takafumi
    Department of Breast Surgical Oncology, Kyushu University Hospital
  • Ochiai Yurina
    Department of Breast Surgical Oncology, Kyushu University Hospital
  • Sato Yo
    Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University
  • Otsubo Yoshiki
    Department of Breast Surgical Oncology, Kyushu University Hospital
  • Hayashi Saori
    Department of Breast Surgical Oncology, Kyushu University Hospital Department of Clinical Genetics and Medicine, Kyushu University Hospital
  • Yamada Mai
    Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University
  • Matsuzaki Sawako
    Department of Clinical Genetics and Medicine, Kyushu University Hospital
  • Nakamura Masafumi
    Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University Department of Breast Surgical Oncology, Kyushu University Hospital
  • Kubo Makoto
    Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University Department of Breast Surgical Oncology, Kyushu University Hospital Department of Clinical Genetics and Medicine, Kyushu University Hospital

Bibliographic Information

Other Title
  • 当院における<i>BRCA</i>遺伝学的検査の現状とその特徴

Search this article

Description

<p>　Hereditary breast and ovarian cancer (HBOC) is an autosomal dominant form of cancer susceptibility syndrome, which is caused by germline pathological variants of BRCA1 or BRCA2 in the narrow sense of the term. The selection of patients for BRCA examination to confirm HBOC is based on the HBOC practice guidelines of the Japanese Organization for Comprehensive Treatment of Hereditary Breast and Ovarian Cancer and the testing criteria of the NCCN guidelines, which differ in some respects, and therefore, so do the test subjects. The criteria for testing are partially different between the two guidelines, so the target population for testing is also different. In this study, we examined the degree to which both testing criteria were met in 58 of 220 patients who were tested positive for BRCA between January 2019 and November 2022 at our hospital. The number of BRCA1/2-positive patients who did not meet the HBOC and NCCN guidelines did not differ significantly, but there were some patients who did not meet the criteria due to cancer or family history of cancer. We believe that the testing criteria should be reviewed in order to increase the number of BRCA-positive patients in the future.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top